Rebound or Brick? Hemispherx Biopharma |
 |
 |
| By Vinny Cassano |
| Wednesday, 04 November 2009 16:31 |
 Shares of Hemispherx BioPharma, Inc (AMEX:HEB) rebounded slightly on Wednesday morning after sliding down to near the $1 mark on Tuesday- after it was announced that the company would spend the next two months responding to FDA queries regarding the company's New Drug Application for Ampligen.
Ampligen is up for approval as a treatment for Chronic Fatigue Syndrome.While Ampligen draws the news for Hemispherx at this time, the company also has already received FDA approval for Alferon, an injection that treats a category of sexually transmitted diseases. Both Ampligen and Alferon are also being evaluated in various early, middle and late stage trials to measure their effectiveness in treating various chronic diseases and viral disorders. The last time that I commented on HEB, the stock was trading for over two dollars and I thought that buying in for the first time at that point was a little too risky, in addition to my aversion to "stock chasing", but since the stock has dropped down to the one dollar level I believe there is potential for HEB to become a nice rebound play. I don't consider an Ampligen approval for CFS a slam dunk, but I do consider the approval as "necessary" to the company's survival in the sense that if they got a positive nod, HEB could then advance the rest of their clinical pipeline without having to raise significant funds. That would likely mean vicious dilution, in my opinion. It's hard to judge when an FDA decision will be rendered, but it's safe to say that if Hemispherx is still responding to inquiries, and will be doing so for the next two months, so a decision some time in middle of 2010 is not out of the question. The stock could be in for some continued volatility, so I'd buy a few shares while it is trading in the lower $1 range, then see how it plays out. With manipulation rampant in the sector these days, a dip to below one dollar is not out of the question, but neither is a speculative spike to near two dollars. As with all speculative stocks, it's a good idea to have already banked some profit and be fully on 'house money' by the time the FDA decision hits; if you've got some 'trading shares' on hand, then try to use them. Sometimes you'll miss out on a run if you've already sold some trading shares into a spike - but that's why you keep your 'base' shares in place, so you don't miss out completely. Conversely, if you've taken some profit during a runup, a subsequent drop in price won't hit you as hard. All just my opinion, of course. Do your own DD before buying. Disclosure: No Positions BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
about 2 hours ago
A Stem-Cell-Based Drug Gets Approval in Canada $OSIR http://t.co/XI3gAfMY
about 3 hours ago
$JNJ Zytiga, a Prostate Cancer Drug, Does Well in Trial http://t.co/v7YUm9b6
about 4 hours ago
$PFE Pfizer Lung Drug Stops Deadly Child Cancers in Study | http://t.co/hcfdrnCY
about 5 hours ago
Human Genome Looks to Anyone but GlaxoSmithKline | http://t.co/d4IMkIn3
about 6 hours ago
When David Einhorn did not mention Herbalife $HLF as a potential short candidate, that stock shot up on Wednesday | http://t.co/XpFKihQS
about 7 hours ago
Stock Market: Stocks Get Hammered On Disappointing Data, Greece Worries http://t.co/FyH8zpru
about 7 hours ago
Synergy Pharmaceuticals (SGYP) May Be Ready To Roll - Small Cap Stock Market Investing Tips http://t.co/FHYXlF1Q
about 10 hours ago
Alvine Presents Results from Phase 2A Trial of ALV003 in Celiac Disease Patients -2012 Digestive Diseases Week Meeting http://t.co/e6Rjhbj9
Free Phone Trade Alerts
